Explore
Premium
Sign Up
Log In
Update on Clinical Trials With Novel CETP Inhibitors to Raise HDL: Where Are We Today? - H. Bryan Brewer
↳ This is a section part of Moment:
CRT 2017: ATHEROSCLEROSIS, PHYSIOLOGY AND IMAGING - Atherosclerosis & Lipid Management
Add this Moment to your Passport
Learn from this moment and keep it forever.
Add To Passport
$15.99
This moment is included in Simple Premium - Get started for free.
FREE
with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments.
$30.00 per month. Cancel anytime.
Preview
Summary
Update on Clinical Trials With Novel CETP Inhibitors to Raise HDL: Where Are We Today? - H. Bryan Brewer at CRT 2017.
Add this Moment to your Passport
Learn from this moment and keep it forever.
Add To Passport
$15.99
This moment is included in Simple Premium - Get started for free.
FREE
with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments.
$30.00 per month. Cancel anytime.
Target Audience
Cardiologists
Interventional Cardiologists
Interventional Fellows
Interventional Radiologists
Vascular Surgeons
Physicians with an interest in Cardiovascular Innovations
Learning Objectives
Other Components in this Moment
Overview
Where are the Guidelines Going and Should We Forget the HDL Story/CETP Inhibition? - Michael Davidson
PCSK9 Inhibitors: Review of the Clinical Trials - Why Are We So Excited? - Steven Nissen
Do PCSK9 Inhibitors Cause Cognitive Impairment? - Michael Lipinski
Cardiotoxicity of Tyrosine Kinase Inhibitors: Novel Mechanisms and Implications for Atherosclerosis - Ori Ben-Yehuda
Lipoprotein(a): Genes, Biological Role, Predictive Value and Drug Interventions - Evan Stein
Update on HDL Infusions and Atherosclerosis Regression in the ACS Patient - H. Bryan Brewer
Achieving Lipid Targets with PCSK9 Inhibition: Is Lower Always Better? - Michael Lipinski
Prospects for CV Risk Factor Reduction with PCSK9 and CETP Inhibitor Therapies - A. Michael Lincoff
Are the PCSK9 Inhibitors the Panacea of Atherosclerosis Treatment? Effects on Lipid Lowering and Beyond - Evan Stein
Update on Clinical Trials With Novel CETP Inhibitors to Raise HDL: Where Are We Today? - H. Bryan Brewer
Loading Simple Education